Genentech Xolair May Get FDA Advisory Committee Review In April

Genentech is planning to submit additional platelet monitoring data from trials of its asthma agent Xolair in time for a potential FDA advisory committee review in late April. FDA has tentatively scheduled a meeting of its Pulmonary-Allergy Drugs Advisory Committee for April 26-27.